Skip to content
← Childhood Cancer Genomics (PDQ®)

HEALTH PROFESSIONAL · SOURCE READING

H3.3 (H3F3A) variant at G34

Source: Childhood Cancer Genomics (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 30, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Central Nervous System Tumors / Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors / Molecular features of pediatric-type high-grade gliomas / Subgroups identified using DNA methylation patterns

The H3.3 G34 subtype arises from H3.3 glycine 34 to arginine/valine (G34R/V) variants.[36,37] This subtype presents in older children and young adults (median age, 14–18 years) and arises exclusively in the cerebral cortex.[36,37] H3.3 G34 cases commonly have variants in TP53 and ATRX (95% and 84% of cases, respectively, in one large series) and show widespread hypomethylation across the whole genome. In a series of 95 patients with the H3.3 G34 subtype, 44% of patients also had a variant in PDGFRA at the time of diagnosis, and 81% of patients had PDGFRA variants observed at relapse.[47]

Source links and citations

Patients with H3F3A variants are at high risk of treatment failure,[48] but the prognosis is not as poor as that of patients with histone 3.1 or 3.3 K27M variants.[37] O-6-methylguanine-DNA methyltransferase (MGMT) methylation is observed in approximately two-thirds of cases, and aside from the IDH1-altered subtype (see below), the H3.3 G34 subtype is the only pediatric high-grade glioma subtype that demonstrates MGMT methylation rates exceeding 20%.[10]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice